

COVID-19 VACCINE UPDATES FOR SCC PROVIDERS

Santa Clara County Public Health Department

Marty Fenstersheib, MD
Jennefer Yoon, PharmD
Teresa Chagoya, MPH

COVID-19 Vaccination Planning Overview

2

- ❑ Vaccination Status
- ❑ Clinical Updates
- ❑ Allocation of Pediatric Pfizer Doses
- ❑ Pediatric Vaccination Planning Updates
- ❑ Ordering, Storage and Handling Updates
- ❑ Other Resources

Santa Clara County Vaccination Status

COVID Cases to Date in SCC (10/20/21)

Cumulative COVID-19 Cases

144,411

7-Day Rolling Average of New Cases

144


Displaying:

Cases

Deaths

Values for the most recent 7 days are preliminary

Cases by Specimen Collection Date




Doses Administered to Date in SCC (10/20/21)

[Link](#)

Residents Ages 12+ With Completed Vaccination	Percent of Residents Ages 12+ With Completed Vaccination	Residents All Ages With Completed Vaccination	Percent of Residents All Ages With Completed Vaccination	Number of Residents with Booster Dose
1,456,274	84.9%	1,456,274	72.9%	70,348

Displaying: Demographics:

COVID-19 Vaccine Doses Administered Over Time Values for the most recent 3 days are preliminary



● First Dose ● Second Dose ● Single Dose ● Booster Dose ● 7-Day Rolling Average of Total Doses Administered

Clinical Updates

Booster Dose vs. Additional Dose

7

Additional Dose: an additional dose of vaccine administered when the immune response following a primary vaccine series is likely to be *insufficient*

- Pfizer and Moderna: authorized
- Janssen: not authorized

Booster Dose: an additional dose of vaccine administered when the initial sufficient immune response to a primary vaccine series is likely to have *waned over time*

- Pfizer: authorized
- Moderna: pending ACIP/CDC
- Janssen: pending ACIP/CDC

No recommendation for boosters for immunocompromised patients who have already received an additional dose. No person should receive more than 3 doses

Booster Eligibility

8

Manufacturer	Eligibility	Dose	Interval	Status
Pfizer	<ul style="list-style-type: none">• 65 years and older• 18 years and older residents of long-term care settings• 18-64 years old with underlying medical conditions• 18-64 years old who work in high-risk settings	0.3 mL (30 ug) [same as primary series]	At least 6 months after the primary series	FDA Authorized CDC Recommended
Moderna*	<ul style="list-style-type: none">• 65 years and older• 18-64 yo at high risk for severe disease• 18-64 yo who work in high-risk settings	0.25 mL (50 ug) [<u>half</u> the dose of the primary series]	At least 6 months after the primary series	FDA Authorized Pending ACIP/CDC Recommendations
Janssen*	<ul style="list-style-type: none">• 18+ yo	0.5 mL [same as initial dose]	At least <u>2 months</u> after the initial dose	FDA Authorized Pending ACIP/CDC Recommendations

*Information subject to change based on ACIP/CDC Recommendations


Heterologous (Mix and Match) Booster Doses

9

- FDA authorized a mix-and-match approach for booster doses on 10/20/21
 - Patients may be able receive any of the three COVID-19 vaccines as a booster dose (*pending ACIP*)
- ACIP is meeting today 10/21/21 to discuss the data and refine the eligibility criteria
- Continue to wait for formal recommendations from CDC

Timeline for Vaccine Authorization

10



*dates subject to change





When to Administer

11

- ❑ (1) Moderna and Janssen booster doses and (2) Pfizer doses for 5-11 year olds may only be administered *after* the CDC has made its formal recommendations
 - Resources: [Interim Clinical Considerations for Use of COVID-19 Vaccine](#)

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

Reference Materials

- [Summary Document for Interim Clinical Considerations](#) 
- [Summary Document for Interim Clinical Considerations poster](#) 
- [COVID-19 Vaccine Administration Errors and Deviations](#) 
- [COVID-19 Vaccine Administration Errors and Deviations Poster](#) 
- [Presentation: Clinical Care Consideration Slides for Healthcare Providers](#) 

Get Email Updates

To receive email updates about this page, enter your email address:

[What's this?](#)

Authorized/Pending Age Groups

12

Pfizer



- 16+ yo: FDA approved
- 12-15 yo: FDA authorized
- 5-11 yo: pending authorization
- <5 yo: ongoing trials

Pfizer for 5-11 year olds pending FDA authorization:

- 2-dose regimen, 21 days apart
- Dose: 10 ug (0.2 mL)
- Formulation: pediatric "Orange Cap" formulation from Pfizer

Moderna



- 18+ yo: FDA authorized
- 12-17 yo: pending authorization
- <12 yo: ongoing trials

Janssen



- 18+ yo: FDA authorized
- 12-17 yo: ongoing trials

Coadministration with COVID-19 vaccines

13

COVID-19 vaccine may be administered with other vaccines, including the influenza vaccine, without regard to timing

It is *unknown* if reactogenicity of COVID-19 vaccines is increased with coadministration

Label each syringe

May administer vaccines in any order

Vaccines likely to cause a local reaction in different limbs

Preferred Site:
Deltoid;
Alternative Site:
anterolateral thigh

Pediatric Vaccination Planning

Potential Pediatric Vaccinators in Santa Clara County


15

167,000+ children ages 5-11 in Santa Clara County

- Large Health Systems
 - El Camino, Kaiser, PAMF, Stanford
- County Health System
 - SCVMC, Valley Health Clinics, Mass Vaccination Sites, Mobile Vax Sites
- Community Health Clinics
- Private Pediatrics and Family Practice Physicians
- School-Based Health Clinics
- Retail & Independent Pharmacies

Provider Onboarding Efforts

16



- Outreached to 350+ providers
- 100+ providers are actively vaccinating patients within SCC

Planning in Progress to Address 5-11 Vaccinations

17

- ❑ **Expanding Vaccine Provider Enrollment** (PH Pharmacy)
- ❑ **Conducting survey to 600 providers through SCCMA**
- ❑ **Partnering with SCCOE and SCC School Districts**
 - **Planning for school-based clinics** (MoVax)
- ❑ **Allocating funding to CHCs and community-based orgs for expanded outreach and vaccination** (PHD IZ)
- ❑ **Creating consistent marketing & communications** (PIO, PH Vaccine Comms)
- ❑ **Conducting provider meetings** (PH Pharmacy)

Allocation of Pediatric Pfizer Doses

Pediatric Pfizer Formulation - Allocations

19

- California received an initial allocation of **1.2 million doses** of pediatric Pfizer to cover 3.6 million 5-11 year olds
- Allocations to occur in 3 waves

Wave	California Allocation	SCC Allocation
1	484,000	15,000
2	363,300	To be released on 10/22
3	363,300	To be released on 10/24

- Pedi vaccine supplied during first 3 waves for SCC residents only**
- Pre-orders open to all COVID vaccine providers via myCAvax
 - Deadline: Friday, 10/22 at 5:00 PM

Ordering, Storage & Handling Updates

Pfizer Pediatric Formulation Pre-Ordering Details

21

- Initial first week supply will be released in 3 waves

Wave	Order By	Shipped By
1	Tuesday, October 19 at 5:00 PM	November 2
2	Thursday, October 21 at 5:00 PM	November 4
3	Friday, October 22 at 5:00 PM	November 8

- Minimum order quantity: 300 doses
 - Place orders for whole week (one order per entity)
- Expectations:
 - Return to open ordering after initial pre-ordering period

myCAvax Vaccine Ordering

22

New Vaccine Order Request

Primary Information

* Account
cassi ceo

* Order Type
Standard Order (CDC)

* Vaccine
Enter Search Key

- Janssen - 100/box COVID-19 Vaccine
- Moderna-140/box - COVID-19 Vaccine
- Pfizer - BioNTech - 450/box - COVID-19 Vaccine
- Pfizer-BioNTech (PED 5-11) - 300/3 boxes of 100 COVID-19 Vaccine**
- Pfizer-BioNTech-1170/box - COVID-19 Vaccine

* Doses Requested




Vaccine	Order Type
Pediatric Pfizer (5-11)	Pre-order period: Standard Order Open-order period: Small Orders
Pfizer (12+)	Small Orders
Moderna	
Janssen	

After initial pre-orders are complete, ordering process will return to normal. Please place all orders using small orders feature.

Pfizer: Current & New Formulations

Table 1. Current and Potential Future Formulations of Pfizer-BioNTech COVID-19 Vaccine³

PRELIMINARY – SUBJECT TO CHANGE PENDING REGULATORY GUIDANCE AND AUTHORIZATION/APPROVAL

Description	Current Formulation	Future Formulations	
	<i>Dilute Prior to Use</i>	<i>Do Not Dilute</i>	<i>Dilute Prior to Use</i>
Age Group	12 years and older	12 years and older	5 to <12 years*
Vial Cap Color	PURPLE 	GRAY 	ORANGE 
Dose	30 mcg	30 mcg	10 mcg
Injection Volume	0.3 mL	0.3 mL	0.2 mL
Fill Volume (before dilution)	0.45 mL	2.25 mL	1.3 mL
Amount of Diluent† Needed per Vial	1.8 mL	NO DILUTION	1.3 mL
Doses per Vial	6 doses per vial (after dilution)	6 doses per vial	10 doses per vial (after dilution)
Storage Conditions			
ULT Freezer (-90°C to -60°C)	9 months	6 months	6 months
Freezer (-25°C to -15°C)	2 weeks	N/A	N/A
Refrigerator (2°C to 8°C)	1 month	10 weeks	10 weeks

†Diluent: Sterile 0.9% Sodium Chloride Injection, USP. Bacteriostatic saline or other diluents must NOT be used.

IMPORTANT INFORMATION:

- The current “Purple Cap” formulation **cannot be used** for children under 12 years of age
- Use of “Purple Cap” formulation to prepare 10 mcg (0.1 mL) doses for 5 to <12 years old has not been studied and is generally considered to be too small for typical IM injections

Moderna Booster: Current Formulation & Ancillary Supplies

24

- ▣ 1 mL syringes must be used for booster doses
 - Primary series = 0.5 mL x2 doses
 - **Booster = 0.25 mL**

- ▣ Ancillary kits will be revised once booster is authorized to include 1 mL syringes
 - Submit request for 1 mL syringe via 213RR if needed

Moderna: Shelf-Life Extension Authorized!

25

- Expiration Extended!
- Additional 2 months at frozen temperature only
 - Extension does not apply to refrigerated Moderna
- Please check and update your expirations using Moderna's [Vial Expiration Date website](#)
 - If expiration is not posted, segregate doses and mark recently "expired" doses as "DO NOT USE pending extension decision"

Other Resources

Upcoming Pfizer Webinars

27

- Upcoming Pfizer-BioNTech COVID-19 Vaccine Training & Education webinars
- **Tuesday, October 26, at 2:00 PM PT**
 - [Click here to join!](#) (code: vuPhUsbD258)
- **Thursday, October 28, at 9:00 AM PT**
 - [Click here to join!](#) (code: 9ywEun8Mjs7)

CDPH COVID-19 Vaccine Office Hours for Providers

28

- ▣ Fridays – 9:00AM to 10:00AM

SESSION NUMBER: 145 195 9307

SESSION PASSWORD: Immunize2021!

Meeting Link: [Click here](#)

AUDIO CONNECTION: 1-415-655-0001

ACCESS CODE: 145 195 9307

- ▣ View archived sessions at: <https://eziz.org/covid/>

Resources Available

29

Submit 213RR for medical supply if you are running low:

- Hand Sanitizer
- Alcohol Swabs
- Cotton Balls
- Bandages
- 1 mL Syringes
- And more...



Provider Resources on EZIZ.org/COVID

Vaccinate ALL 58 California COVID-19 Vaccination Program ENHANCED BY Google

- Program Updates
- Program Enrollment
- My Turn Onboarding
- Vaccine Management
- Vaccine Administration
- Reporting Requirements
- Archived Communications
- Patient Resources

Program Updates

If you need assistance with accessing documents on this website, email covidcallcenter@cdph.ca.gov or call (833) 502-1245 Mon-Fri 8 AM-6 PM.

Program Support and Education

- COVID-19 Vaccination Program FAQs Updated 10/14
- Connect with Vaccine Experts – Provider Office Hours Every Friday
- myCAvax Training
- Weekly Webinars and Training Calendar

Alerts:

Pre-Order Pfizer Vaccine for 5-11 Years of Age

Catch-up pre-ordering is available through Friday, October 22 at 5:00 PM.

- Pre-Orders Available in myCAvax!
- Pre-Ordering and Anticipated Delivery Schedule

CalVaxGrant Deadline Extended to December 17!

- There's still time to apply for Grants Up to \$55,000 for Support of Small Practices

What barriers do you foresee in administering booster doses in the next month?

Please email CovidCallCenter@cdph.ca.gov with your response. Your feedback is appreciated!

- COVID-19 Vaccine Eligibility Chart | Summary of Related Guidance and Requirements
- Are You Ready for Expanded Booster Doses? – Provider Readiness Checklist
- CDPH Town Hall on Booster Dose Readiness | Slides

Now Enrolling Providers of Pediatric Services

- Benefits for Primary Care Providers
- Find Information on How to Enroll

Provider Support

COVID Call Center

Email: [For Program Info](mailto:ForProgramInfo@cdph.ca.gov)
Phone: (833) 502-1245
Hours: Mon-Fri, 8AM-6PM

myCAvax Help Desk

Email: [For Technical Support](mailto:ForTechnicalSupport@cdph.ca.gov)
Phone: (833) 502-1245, option 2

Vaccines

[Manufacturer Contacts](#)

My Turn

Email: [For Onboarding, Technical Support](mailto:ForOnboarding@cdph.ca.gov)
Help Desk: (833) 502-1245, option 4
Mon-Fri: 7AM-7PM
Sat-Sun: 8AM-1PM

Clinic Translation Line:
(833) 980-3933
Mon-Fri: 8AM-8PM
Sun-Sat: 8AM-5PM

Vaccine Management:

- List of Upcoming COVID-19 Vaccine Expiration Dates
- Ordering Vaccines | New Ordering & Distribution Cadence

Thank you!

Questions? Email us at: vaccinebranch@eoc.sccgov.org